Candida Guckelmus
Overview
Explore the profile of Candida Guckelmus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urschel R, Bronder S, Klemis V, Marx S, Hielscher F, Abu-Omar A, et al.
Nat Commun
. 2024 Apr;
15(1):3077.
PMID: 38594497
Knowledge is limited as to how prior SARS-CoV-2 infection influences cellular and humoral immunity after booster-vaccination with bivalent BA.4/5-adapted mRNA-vaccines, and whether vaccine-induced immunity may indicate subsequent infection. In this...
2.
Bronder S, Mihm J, Urschel R, Klemis V, Schmidt T, Marx S, et al.
NPJ Vaccines
. 2024 Feb;
9(1):25.
PMID: 38326340
Knowledge on immunogenicity of the bivalent Omicron BA.4/5 vaccine in dialysis patients and the effect of a previous infection is limited. Therefore, vaccine-induced humoral and cellular immunity was analyzed in...
3.
Hielscher F, Schmidt T, Klemis V, Wilhelm A, Marx S, Abu-Omar A, et al.
J Clin Virol
. 2022 Oct;
157:105321.
PMID: 36279695
Background: The NVX-CoV2373-vaccine has recently been licensed, although knowledge on vaccine-induced humoral and cellular immunity towards the parental strain and variants of concern (VOCs) in comparison to mRNA-regimens is limited....
4.
Klemis V, Schmidt T, Schub D, Mihm J, Marx S, Abu-Omar A, et al.
Nat Commun
. 2022 Aug;
13(1):4710.
PMID: 35953492
Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and...
5.
Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al.
Nat Med
. 2021 Jul;
27(9):1530-1535.
PMID: 34312554
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity...